Thus, in order to make the PTX loading process easier and more profitable, and further reduce the effective doses and the side effects of this drug, a novel PTX-Tmab targeted DDS was developed in the current study to improve HER2+ BC treatment. The gene discussed is ERBB2; the disease is breast cancer.